Persistent Cushing's Disease After Surgery: Choosing Among Three Steroidogenesis Inhibitors
A single patient whose recurrent Cushing's disease has three real medical options, none of which is simply the best choice for everyone — the right one depends on which specific risk and which specific symptom matter most to her.
Priya S., a 43-year-old woman, had transsphenoidal surgery for Cushing's disease fourteen months ago that looked successful at first — her cortisol nadir on postoperative day two was appropriately low — but her hypercortisolism returned within a year, confirmed on repeat testing three weeks ago. A second surgery was discussed and declined; her surgeon's own read of the pituitary MRI is that the residual tissue is too diffusely infiltrative for a clean re-resection, and Priya, having been through one recovery already, wants medical therapy explored before committing to another operation with a lower expected success rate. What bothers her most day to day isn't the fatigue or the weight gain, both of which she has adjusted her expectations around, but a new coarse dark hair growth along her jaw and upper lip that started roughly the same time her labs turned again — real hyperandrogenism, and something she brings up unprompted at every visit.
Three steroidogenesis inhibitors are realistic options, and the choice among them is not a clean hierarchy. Creemers et al.'s in vitro work showed osilodrostat inhibits cortisol production roughly twice as potently as metyrapone and about eighteen times more potently than ketoconazole, and a large 2024 real-world comparison, the MOSKETEER study (Detomas et al., 531 patients across twenty centers), found the three agents lowered urinary free cortisol comparably at lower doses, with osilodrostat pulling ahead of metyrapone only once doses were pushed higher — a narrower advantage than the potency figures alone would suggest. But potency isn't the only axis that matters for Priya specifically: metyrapone's own mechanism drives accumulation of androgen precursors upstream of the enzyme it blocks, worsening exactly the hirsutism she is most bothered by, while ketoconazole is the agent the literature specifically flags as preferred in women partly because it can improve hirsutism rather than worsen it — set against ketoconazole's own real hepatotoxicity risk, relevant given the mild hepatic steatosis her last routine ultrasound already showed, well short of the severe liver disease that actually contraindicates it.
Endocrinology follow-up, choosing a medical regimen
Creemers' in vitro work puts osilodrostat at roughly twice the potency of metyrapone and eighteen times that of ketoconazole, and MOSKETEER — Detomas' 531-patient real-world comparison — found it pulled ahead on urinary free cortisol at higher doses, though the three were much closer at the doses most patients actually start on. It also doesn't share metyrapone's mechanism of driving androgen precursors upstream — which matters directly here, since her hirsutism is what she keeps bringing up.
I'd actually go further on that same symptom and reach for ketoconazole. It's the agent the literature specifically names as preferred in women, in part because it can improve hirsutism and menstrual irregularity rather than just avoid worsening them. Her hepatic steatosis is mild — LFTs are still normal — and that's not the severe liver disease ketoconazole's own warning is actually about; routine monitoring should catch a problem long before it becomes one.
I take the MOSKETEER data seriously — I'm not disputing osilodrostat's potency — I just don't think potency is the axis that should decide this for a patient whose main complaint is a symptom ketoconazole is specifically documented to help.
Both of you are right about a real advantage, and both drugs also carry a real, specific risk for her — osilodrostat's own documented adrenal insufficiency risk on titration, ketoconazole's hepatotoxicity risk against a liver that, however mildly, is already not entirely normal. I don't think the data cleanly separates them for her profile. What I'd actually ask Priya is which monitoring schedule she can realistically keep — frequent early titration visits for one, routine LFTs for the other — because either drug started and monitored properly is a reasonable choice, and the one she'll actually stay on is the one that works.
Agreed: start ketoconazole with a defined liver-monitoring schedule and cortisol checks at each titration step, with Priya's own preference — informed by both options' real risks and benefits — as the deciding factor between the two viable candidates.
Not agreed: what should happen if her LFTs rise into a concerning but not clearly dangerous range. The women's health physician would favor a dose reduction and closer monitoring before abandoning the drug outright; the endocrinologist would rather switch to osilodrostat at that point rather than continue titrating a hepatotoxic agent against early warning signs.